Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

July 11, 2024

Primary Completion Date

July 31, 2029

Study Completion Date

July 31, 2029

Conditions
NeuroblastomaSarcomaOsteosarcoma
Interventions
DRUG

B7-H3CART Dose (Intravenous)

"Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level -1 (DL-1) 0.3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 1 (DL1) 1 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 2 (DL2) 3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 2 (DL2) 3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 3 (DL3) 9 x 106 transduced T cells/kg"

Trial Locations (1)

94304

RECRUITING

Stanford University, Palo Alto

All Listed Sponsors
lead

Crystal Mackall, MD

OTHER